Publications by authors named "E Hadaschik"
[Recurrent, painful ulcers of the lower extremities and abdomen].
Dermatologie (Heidelb)
December 2024
Article Synopsis
- Researchers studied patients with advanced skin cancer (melanoma) to see how well they responded to a special treatment called immune checkpoint inhibition (ICI).
- They found that only about 8% of patients responded quickly to the treatment, while others had slower responses or did not respond at all.
- Despite the quick responders showing some improvement, they didn’t live longer or have better outcomes than those who responded later to the treatment.
Background: Melanomas lacking mutations in BRAF, NRAS and NF1 are frequently referred to as "triple wild-type" (tWT) melanomas. They constitute 5-10 % of all melanomas and remain poorly characterized regarding clinical characteristics and response to therapy. This study investigates the largest multicenter collection of tWT-melanomas to date.
View Article and Find Full Text PDFArticle Synopsis
- Screening for gene mutations in melanoma has become standard practice, with identified mutations impacting prognosis in metastatic uveal melanoma, while their significance in non-uveal melanoma is still unclear.
- A study analyzing 2,650 melanoma cases found mutations in 129 samples, highlighting differences in the prevalence and types of mutations between uveal and non-uveal melanomas.
- Unlike uveal melanomas, where mutations are linked to worse outcomes, mutations in non-uveal melanomas are mostly seen as "passenger mutations" with little impact on prognosis or treatment effectiveness.
Melanoma causes the majority of skin cancer-related deaths. Despite novel therapy options, metastatic melanoma still has a poor prognosis. Immune checkpoint inhibition (ICI) therapy has been shown to prolong overall survival in patients with advanced melanoma, but mucosal melanomas respond less favorably compared to melanomas of cutaneous origin.
View Article and Find Full Text PDF